Cochrane · systematic review · CD013613
Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals experiencing acute traumatic stress symptoms
Bertolini, F, Robertson, L, Bisson, JI, et al. · Cochrane Database of Systematic Reviews · 2024 · Cochrane Library
Common Mental DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
7
No studies
3
Included studies
NR
No studies 3 · 30%Ungraded 0 · 0%Very low 6 · 60%Low 1 · 10%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Escitalopram compared to placebo for the prevention of PTSD in individuals experiencing acute traumatic stress symptoms
Population: adults experiencing acute traumatic stress symptoms
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PTSD severity at 3 months Escitalopram vs placebo | no estimate extracted | 1 study · 23 participants | Very low Downgraded: risk of bias |
Dropouts due to adverse events at 3 months Escitalopram vs placebo | no estimate extracted | 1 study · 31 participants | Very low Downgraded: risk of bias |
PTSD rate at 3 months Escitalopram vs placebo | RR 0.59 [0.03, 13.08] | 1 study · 23 participants | Very low Downgraded: risk of bias |
Functional disability at 3 months ‐ not measured Escitalopram vs placebo | no estimate extracted | NR | No studies |
Quality of life at 3 months ‐ not measured Escitalopram vs placebo | no estimate extracted | NR | No studies |
Hydrocortisone compared to placebo for prevention of PTSD in individuals experiencing acute traumatic stress symptoms
Population: adults experiencing acute traumatic stress symptoms
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PTSD severity at 3 months Hydrocortisone vs placebo | no estimate extracted | 3 studies · 136 participants | Very low Downgraded: risk of bias |
Dropouts due to adverse events at 3 months Hydrocortisone vs placebo | RR 3.19 [0.13, 75.43] | 2 studies · 182 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
PTSD rate at 3 months Hydrocortisone vs placebo | RR 0.47 [0.09, 2.38] | 3 studies · 136 participants | Very low Downgraded: risk of bias |
Functional disability at 3 months ‐ not measured Hydrocortisone vs placebo | no estimate extracted | NR | No studies |
Quality of life at 3 months Hydrocortisone vs placebo | no estimate extracted | 1 study · 43 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |